ArticleScientific reports2025
Elevated SLC4A11 expression promotes OV progression via interaction with EGFR.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ovarian cancer (OV) is one of the most prevalent and lethal gynecological malignancies worldwide, often diagnosed at advanced stages due to its asymptomatic early progression. Despite standard treatments, including tumor reduction surgery and platinum-based chemotherapy, the majority of patients face high risks of recurrence and metastasis, underscoring the need for a deeper understanding of the molecular mechanisms driving OV progression. This study focused on Solute Carrier Family 4 Member 11 (SLC4A11), a gene highly expressed in OV, to explore its functional role and underlying mechanisms. Analysis of public datasets (TCGA and GEO) revealed that SLC4A11 expression was significantly elevated in OV tissues compared to normal tissues and was associated with poorer overall survival and advanced clinical stages. Functional in vitro assays, including colony formation, migration, and CCK-8 experiments, demonstrated that SLC4A11 overexpression enhanced OV cell proliferation and migration, while its knockdown inhibited these processes. In vivo studies using a subcutaneous xenograft mouse model further validated the role of SLC4A11 in promoting tumor growth. Mechanistically, SLC4A11 was found to directly interact with the Epidermal growth factor receptor (EGFR), activating the PI3K/AKT signaling pathway, a critical driver of cancer progression. These findings highlight SLC4A11 as a key regulator of OV development and a potential therapeutic target, offering new insights for improving treatment strategies and patient outcomes in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.